BDBM101091 US10189794, Compound I-247::US10618902, Compound I-247::US10774052, Compound I-247::US9695132, I-247

SMILES CN1C(=O)N(Cc2cnc(NC3COCC3NC(=O)C=C)nc12)c1cc(ccc1Cl)C(=O)Nc1cccc(c1)C(C)(C)C

InChI Key InChIKey=QPXOAOSUYWNFPI-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 101091   

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101091(US10189794, Compound I-247 | US10618902, Compound ...)
Affinity DataIC50:  251nMpH: 7.5Assay Description:Omnia Assay Protocol for Potency Assessment Against FGFR 4 Enzyme. a) [FGFR4-WT]=10 nM, [ATP]=300 uM, [Y10-Sox]=10 uM (ATP KMapp 300 uM): A 10x stock...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101091(US10189794, Compound I-247 | US10618902, Compound ...)
Affinity DataIC50:  300nMAssay Description:For MDA-MB-453 cells signaling, cells were grown in 96-well poly-D-lysine plates (BD Bioscience, San Jose, Calif.) to 90% confluence, and were then i...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101091(US10189794, Compound I-247 | US10618902, Compound ...)
Affinity DataIC50:  2.75E+3nMAssay Description:A 10× stock solution of FGFR4-WT (PR4380C or P3054), (from Invitrogen, Carlsbad, Calif.) corresponding to method a in Table 10, was prepared as descr...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetFibroblast growth factor receptor 4(Human)
Celgene Car

US Patent
LigandPNGBDBM101091(US10189794, Compound I-247 | US10618902, Compound ...)
Affinity DataIC50:  300nMAssay Description:A 10× stock solution of FGFR4-WT (PR4380C), (from Invitrogen, Carlsbad, Calif.) corresponding to method a in Table 7, was prepared as described below...More data for this Ligand-Target Pair
In DepthDetails US Patent